|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shawn Cain, SVP Development & Manufacturing at PCI Pharma Services, discusses the recent acquisition, the opportunities this presents to Biopharma companies, and the current trends in the sterile fill-finish industry.
|
|
|
Rich Ellson and John Fuller, PhD, say accelerating development comes down to designing and using flexible automation solutions along with smarter instruments and new consumable paradigms to help meet researchers’ needs.
|
|
|
Tom Sellig, CEO at Adare Pharma Solutions, discusses his expectations for Adare and how he can leverage his 30-plus years of pharma experience to put Adare in a competitive position to address complex formulation and development challenges.
|
|
|
Bill Vincent believes if the industry wants to keep moving up the steep growth curve, then capacity and raw materials must be readily available. The innovations in therapies, platforms, and processes will all come with time, money, and increasing availability of resources.
|
|
|
|
|
|
|
|
|

Intertek’s Pharmaceutical Services laboratory in Whitehouse, NJ, is an FDA- and DEA-registered cGMP-compliant facility, specializing in complex and routine services to support the development of drug products, formulations, medical devices, and drug delivery systems for clients globally. We have pharmaceutical expertise for various GMP and CMC testing, including method development and validation, stability, extractables and leachables, and elemental impurities. Partnering with our Whitehouse facility brings the assurance, confidence, and peace of mind that comes with collaborating with a current good manufacturing practice (cGMP) compliant facility, ensuring that testing will be carried out to the most up-to-date and highest quality standards, preserving the integrity of your products. Click here for more.
|
|
|
|
|
|
 |
|
Pharmazz, Inc. recently announced positive topline results of its Phase 3 clinical trial evaluating sovateltide as a treatment for acute ischemic stroke. The data at 90 days showed….
|
|
 |
|
Dermavant Sciences recently announced the US FDA has approved VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes….
|
|
 |
|
Clearmind Medicine Inc. recently announced positive safety profile results from its joint preclinical trial with SciSparc Ltd. The trial evaluated the proprietary combination of Clearmind’s proprietary psychedelic molecule….
|
|
 |
|
Innoviva, Inc. and Entasis Therapeutics Holdings Inc. recently announced the companies have entered into a definitive merger agreement under which Innoviva is to acquire all….
|
|
|
|
|
|
|
|
 |
|
As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….
|
|
 |
|
Emergent and groniger partner to present the benefits and features of the INTEGRA® high-speed aseptic fill line with isolator technology for viral vaccines and therapeutics.
|
|
|
|
|
|
|
|
 |
|
The Proveris by Design™ process offers a formalized approach to product development, all the while automating in vitro testing, and streamlining troubleshooting. It is an indispensable tool for successfully developing nasal spray and inhalation drug products as well as critical …
|
|
 |
|
Nanoparticles offer multi-functional capabilities that include the ability to be tracked within the body, deliver a specific compound at a controlled rate, target a particular location, and remotely kill cells once in place due to which their use as drug …
|
|
 |
|
Achieving good in vivo performance is a key attribute for ensuring safety and efficacy of oral solid dosage (OSD) forms intended for systemic delivery. Yet, new drug targets and mechanisms of action continue to drive drug candidates’ physical properties toward …
|
|
|
|
|
Upcoming eNewsletter Features:
June 8 – Injection Devices
June 15 – Parenteral Contract Manufacturing
|
|
|
|
|
|
|
|